. In an effort to help overcome these barriers, the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Palliative Care recommend that all patients with cancer be screened for PC needs, and consultation or collaboration with a PC
Search Results
Paul Glare, Kathy Plakovic, Anna Schloms, Barbara Egan, Andrew S. Epstein, David Kelsen, and Leonard Saltz
Demetra Hypatia Hufnagel, Sumit Tushar Mehta, Chinyere Ezekwe, Alaina J. Brown, Alicia Beeghly-Fadiel, and Lauren Shore Prescott
is lacking. In a prospective study of 15,000 patients with cancer, 39% had anemia at initial presentation; however, only 40% of those with anemia received treatment. 2 The current NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for
David J. Worhunsky, Yifei Ma, Yulia Zak, George A. Poultsides, Jeffrey A. Norton, Kim F. Rhoads, and Brendan C. Visser
Clinical Practice Guidelines in Oncology (NCCN Guidelines) provide recommendations based on the best evidence available at the time they are derived and on expert consensus. These guidelines are continuously updated and revised to reflect new data and
Craig S. Schneider, Robert A. Oster, Aparna Hegde, Michael C. Dobelbower, John M. Stahl, and Adam J. Kole
evaluating the role of chemotherapy are lacking. As a result, based on extrapolations of surgical data, NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for NSCLC recommend the consideration of chemotherapy for high-risk patients with
Robert J. Morgan Jr., Ronald D. Alvarez, Deborah K. Armstrong, Barry Boston, Robert A. Burger, Lee-may Chen, Larry Copeland, Marta Ann Crispens, David Gershenson, Heidi J. Gray, Perry W. Grigsby, Ardeshir Hakam, Laura J. Havrilesky, Carolyn Johnston, Shashikant Lele, Ursula A. Matulonis, David M. O'Malley, Richard T. Penson, Steven W. Remmenga, Paul Sabbatini, Russell J. Schilder, Julian C. Schink, Nelson Teng, and Theresa L. Werner
be considered in treatment guidelines. The NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Ovarian Cancer discuss epithelial ovarian cancer (including borderline or low malignant potential) and less-common histopathologies
Robert B. Hines, Alina Barrett, Philip Twumasi-Ankrah, Dominique Broccoli, Kimberly K. Engelman, Joaquina Baranda, Elizabeth A. Ablah, Lisette Jacobson, Michelle Redmond, Wei Tu, and Tracie C. Collins
, and race on the risk of patient nonadherence with NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Colon/Rectal Cancer. It also assesses the effect of nonadherence to treatment guidelines and the aforementioned risk factors on
Robert W. Carlson, D. Craig Allred, Benjamin O. Anderson, Harold J. Burstein, W. Bradford Carter, Stephen B. Edge, John K. Erban, William B. Farrar, Andres Forero, Sharon Hermes Giordano, Lori J. Goldstein, William J. Gradishar, Daniel F. Hayes, Clifford A. Hudis, Britt-Marie Ljung, David A. Mankoff, P. Kelly Marcom, Ingrid A. Mayer, Beryl McCormick, Lori J. Pierce, Elizabeth C. Reed, Jasgit Sachdev, Mary Lou Smith, George Somlo, John H. Ward, Antonio C. Wolff, and Richard Zellars
Overview These NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Breast Cancer are the work of the members of the NCCN Breast Cancer Panel. Categories of evidence and consensus were assessed and are noted in the algorithms
Adam J. Kole, John M. Stahl, Henry S. Park, Sajid A. Khan, and Kimberly L. Johung
recommended definitive CRT for all patients with locoregional anal canal cancer since the inception of the second version of the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Anal Carcinoma in 2002. 2 , 17 Whether NCCN Guidelines are
Barbara Dull, Andrew Linkugel, Julie A. Margenthaler, and Amy E. Cyr
%. 1 In this group of patients, the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) recommend standard imaging with diagnostic bilateral mammography and ultrasound; breast MRI may also be used. 3 Additional staging studies are only
Philippe E. Spiess, Neeraj Agarwal, Rick Bangs, Stephen A. Boorjian, Mark K. Buyyounouski, Peter E. Clark, Tracy M. Downs, Jason A. Efstathiou, Thomas W. Flaig, Terence Friedlander, Richard E. Greenberg, Khurshid A. Guru, Noah Hahn, Harry W. Herr, Christopher Hoimes, Brant A. Inman, Masahito Jimbo, A. Karim Kader, Subodh M. Lele, Joshua J. Meeks, Jeff Michalski, Jeffrey S. Montgomery, Lance C. Pagliaro, Sumanta K. Pal, Anthony Patterson, Elizabeth R. Plimack, Kamal S. Pohar, Michael P. Porter, Mark A. Preston, Wade J. Sexton, Arlene O. Siefker-Radtke, Guru Sonpavde, Jonathan Tward, Geoffrey Wile, Mary A. Dwyer, and Lisa A. Gurski
This selection from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Bladder Cancer focuses on systemic therapy for muscle-invasive urothelial bladder cancer, as substantial revisions were made in the 2017 updates, such as new recommendations for nivolumab, pembrolizumab, atezolizumab, durvalumab, and avelumab. The complete version of the NCCN Guidelines for Bladder Cancer addresses additional aspects of the management of bladder cancer, including non–muscle-invasive urothelial bladder cancer and nonurothelial histologies, as well as staging, evaluation, and follow-up.
